Trials / Recruiting
RecruitingNCT06055920
The PEERLESS II Study
PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,200 (estimated)
- Sponsor
- Inari Medical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | FlowTriever System | Mechanical Thrombectomy for pulmonary embolism |
| DRUG | Anticoagulation Agents | Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Timeline
- Start date
- 2023-11-17
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2023-09-28
- Last updated
- 2026-04-06
Locations
83 sites across 9 countries: United States, Belgium, Canada, Denmark, France, Germany, Poland, Spain, Switzerland
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT06055920. Inclusion in this directory is not an endorsement.